Overview

Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Status:
Suspended

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Dapagliflozin